LeadIQ logo
Learn more at LeadIQ.com

Insights

Acquisition Opportunities Albireo Pharma, Inc. has recently been acquired by Ipsen and Amgen Foundation, indicating a strategic focus on rare disease therapies. This presents an opportunity for partnerships or collaborations with these larger pharmaceutical companies to expand market reach and access new distribution channels.

Expanded Product Portfolio With the acquisition and development of innovative therapies like Bylvay for rare liver diseases, Albireo Pharma has diversified its product portfolio. This expansion provides an opening to target healthcare providers specializing in pediatric and adult liver diseases who seek novel treatment options for their patients.

Key Leadership Appointments The recent appointments of Ron Cooper as President and CEO, and Susan Alesina to the Board of Directors, bring extensive experience in biopharma business development and commercialization. Leveraging these key personnel connections could lead to potential collaborations or distribution agreements with industry leaders in the biotechnology sector.

Grant-Based Initiatives Albireo Pharma's launch of the SPARK program to drive improvements in rare liver disease care offers an avenue for engagement with healthcare institutions, patient advocacy groups, and research organizations. Exploring sponsorship or partnership opportunities within the SPARK initiative can enhance brand visibility and foster goodwill in the medical community.

Financial Stability and Growth With a revenue range of $10-50 million and recent funding of $45 million, Albireo Pharma has demonstrated financial stability and growth potential. This financial health positions the company as a reliable partner for potential investors, healthcare institutions, and distributors looking to align with a promising player in the biotechnology research space.

Similar companies to Albireo Pharma, Inc.

Albireo Pharma, Inc. Tech Stack

Albireo Pharma, Inc. uses 8 technology products and services including Microsoft Dynamics, React, Modernizr, and more. Explore Albireo Pharma, Inc.'s tech stack below.

  • Microsoft Dynamics
    Enterprise Resource Planning
  • React
    Javascript Frameworks
  • Modernizr
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • web-vitals
    Javascript Libraries
  • Amazon Web Services
    Platform As A Service
  • HSTS
    Security
  • Google Tag Manager
    Tag Management

Media & News

Albireo Pharma, Inc.'s Email Address Formats

Albireo Pharma, Inc. uses at least 1 format(s):
Albireo Pharma, Inc. Email FormatsExamplePercentage
First.Last@albireopharma.comJohn.Doe@albireopharma.com
87%
Last@albireopharma.comDoe@albireopharma.com
8%
First.Middle@albireopharma.comJohn.Michael@albireopharma.com
3%
First@albireopharma.comJohn@albireopharma.com
2%

Frequently Asked Questions

Where is Albireo Pharma, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Albireo Pharma, Inc.'s main headquarters is located at 53 State Street 19th Floor Boston, Massachusetts 02109 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Albireo Pharma, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Albireo Pharma, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Albireo Pharma, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Albireo Pharma, Inc.'s official website is albireopharma.com and has social profiles on LinkedIn.

How much revenue does Albireo Pharma, Inc. generate?

Minus sign iconPlus sign icon
As of December 2023, Albireo Pharma, Inc.'s annual revenue reached $41M.

What is Albireo Pharma, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Albireo Pharma, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Albireo Pharma, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2023, Albireo Pharma, Inc. has approximately 107 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Vice President Of Financial Planning Analysis: C. M.Vice President Pharmaceutical Development: J. B.Vice President Finance, Global: R. C. A.. Explore Albireo Pharma, Inc.'s employee directory with LeadIQ.

What industry does Albireo Pharma, Inc. belong to?

Minus sign iconPlus sign icon
Albireo Pharma, Inc. operates in the Biotechnology Research industry.

What technology does Albireo Pharma, Inc. use?

Minus sign iconPlus sign icon
Albireo Pharma, Inc.'s tech stack includes Microsoft DynamicsReactModernizrjQueryweb-vitalsAmazon Web ServicesHSTSGoogle Tag Manager.

What is Albireo Pharma, Inc.'s email format?

Minus sign iconPlus sign icon
Albireo Pharma, Inc.'s email format typically follows the pattern of . Find more Albireo Pharma, Inc. email formats with LeadIQ.

How much funding has Albireo Pharma, Inc. raised to date?

Minus sign iconPlus sign icon
As of December 2023, Albireo Pharma, Inc. has raised $45M in funding. The last funding round occurred on May 24, 2017 for $45M.
Albireo Pharma, Inc.

Albireo Pharma, Inc.

Biotechnology ResearchMassachusetts, United States51-200 Employees

On March 2, 2023, Albireo was acquired by Ipsen, strengthening Ipsen’s rare disease portfolio with promising therapeutics for pediatric and adult rare liver diseases.

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome (ALGS), an ongoing Phase 3 study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.  

Section iconCompany Overview

Headquarters
53 State Street 19th Floor Boston, Massachusetts 02109 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $45M

    Albireo Pharma, Inc. has raised a total of $45M of funding over 2 rounds. Their latest funding round was raised on May 24, 2017 in the amount of $45M.

  • $10M$50M

    Albireo Pharma, Inc.'s revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $45M

    Albireo Pharma, Inc. has raised a total of $45M of funding over 2 rounds. Their latest funding round was raised on May 24, 2017 in the amount of $45M.

  • $10M$50M

    Albireo Pharma, Inc.'s revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.